The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY)

In by ECIR

The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY)

  • This field is for validation purposes and should be left unchanged.

A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease

clinicaltrials.gov

Eligibility

Inclusion Criteria

• Age ≥18 years
• Evidence of chronic kidney disease with eGFR ≥20 to <45 mL/min/1.73m² or <90 mL/min/1.73m²

Exclusion Criteria

• Currently receiving SGLT-2 or SGLT-1/2 inhibitor
• Type 2 diabetes mellitus and prior atherosclerotic cardiovascular disease with an eGFR >60 mL/min/1.73m²
• Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant

Back to Current Studies